News | February 16, 2024
Lupin launches Ganirelix Acetate Injection in US
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
The product will be manufactured at Lupin’s Nagpur facility in India
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
